Kornitzer Capital Management Inc. KS Decreases Stock Holdings in Kenvue Inc. $KVUE

Kornitzer Capital Management Inc. KS lessened its stake in Kenvue Inc. (NYSE:KVUE) by 0.9% in the 2nd quarter, Holdings Channel.com reports. The fund owned 76,975 shares of the company’s stock after selling 670 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in Kenvue were worth $1,611,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Kenvue by 4.9% in the first quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company’s stock valued at $5,494,882,000 after purchasing an additional 10,600,682 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Kenvue by 2.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 25,606,238 shares of the company’s stock valued at $613,882,000 after buying an additional 633,461 shares in the last quarter. Boston Partners boosted its holdings in Kenvue by 7.4% in the 1st quarter. Boston Partners now owns 25,346,453 shares of the company’s stock worth $606,920,000 after buying an additional 1,750,490 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Kenvue by 11.6% during the 1st quarter. JPMorgan Chase & Co. now owns 24,912,226 shares of the company’s stock worth $597,395,000 after buying an additional 2,597,920 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in Kenvue by 15.7% during the 1st quarter. American Century Companies Inc. now owns 21,828,854 shares of the company’s stock worth $523,456,000 after buying an additional 2,961,716 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Down 0.6%

Shares of KVUE opened at $15.00 on Monday. Kenvue Inc. has a 52-week low of $14.05 and a 52-week high of $25.17. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The stock has a fifty day simple moving average of $17.91 and a two-hundred day simple moving average of $20.79. The company has a market capitalization of $28.78 billion, a PE ratio of 20.26, a price-to-earnings-growth ratio of 2.16 and a beta of 0.72.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The firm had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. During the same quarter in the prior year, the firm posted $0.32 earnings per share. Kenvue’s quarterly revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.5%. The ex-dividend date of this dividend was Wednesday, August 13th. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio is 112.16%.

Analyst Ratings Changes

KVUE has been the topic of a number of research analyst reports. UBS Group lowered their price target on Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 8th. Evercore ISI decreased their price objective on Kenvue from $23.00 to $18.00 and set an “in-line” rating on the stock in a report on Tuesday, September 23rd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a research note on Tuesday, October 14th. Zacks Research upgraded shares of Kenvue to a “strong sell” rating in a research report on Monday, August 11th. Finally, Royal Bank Of Canada decreased their price target on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $20.75.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.